Brazil, Nigeria key pharma export destinations for India: Report
Country's pharma exports up by 6.5% to $ 20.48 bn during April-Nov 2025-26
image for illustrative purpose
New Delhi: Brazil and Nigeria are emerging as key export destinations for Indian pharmaceutical firms amid global economic uncertainties, according to the commerce ministry data.
Nigeria emerged as one of the fastest growing destinations, adding $ 179 million in exports and contributing over 14 per cent to the total export growth during the first eight months of this fiscal year.
During April-November FY26, Brazil also recorded an increase of nearly $ 100 million exports, the data showed.
"These markets reflect rising healthcare access, expanding public procurement, and growing reliance on Indian generics, reinforcing India's role as a preferred supplier to high growth demand intensive regions," an official said.
The country's pharmaceutical exports rose by 6.5 per cent to $ 20.48 billion during April-November 2025-26.
The data also showed that the US continues to be the single largest destination, accounting for over 31 per cent of exports in April-November 2025, while the overall growth profile highlights a broadening of demand across multiple geographies, strengthening the stability of India's pharma export basket, the official added.
Alongside the US, countries such as France, the Netherlands, Canada, Germany, and South Africa registered steady increase, collectively contributing to export expansion while maintaining stable shares.
Notably, the Netherlands added over $ 58 million in exports, reflecting India's strengthening integration into European pharmaceutical distribution networks. "This combination of scale markets and diversified secondary destinations highlights a balanced export architecture, where growth is supported by both mature healthcare systems and fast expanding emerging economies," the commerce ministry official said.
India’s share of pharmaceuticals and drugs in the global market is 5.71%. Formulations and Biologics constituted the major portion of India’s exports with a share of 79.26% followed by drug intermediates and bulk drugs with a share of 16.08%.
India has the highest number of United States Food and Drug Administration (USFDA) compliant companies with plants outside of the USA.
About eight out of 20 global generic companies are from India and over 55% of the exports from the country are to the highly regulated markets. As the country is the biggest vaccine exporter, about 65-70% of the World Health Organization (WHO) vaccine requirements are sourced from India.
